Nobivac DHP

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Canine adenovirus, Canine distemper virus, Canine parvovirus

Available from:

MSD Animal Health UK Limited

ATC code:

QI07AD02

INN (International Name):

Canine adenovirus, Canine distemper virus, Canine parvovirus

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Live Viral Vaccine

Authorization status:

Authorized

Authorization date:

2005-07-28

Summary of Product characteristics

Revised: February 2022
AN: 00188/2021 & 00189/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac DHP
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES:
Per dose of 1 ml reconstituted vaccine:
Canine distemper virus, strain Onderstepoort
not less than 10
4.0
TCID
50*
Canine adenovirus 2, strain Manhattan LPV3
not less than 10
4.0
TCID
50*
Canine parvovirus, strain 154
not less than 10
7.0
TCID
50*
*Tissue culture infective dose 50%
Solvent (1 ml per vial):
Phosphate buffered saline.
Excipients:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of dogs to reduce clinical signs of
disease caused by
canine distemper virus infection; to prevent clinical signs and viral
excretion caused
by canine parvovirus infection; to reduce clinical signs of canine
contagious hepatitis
and viral excretion due to canine adenovirus 1 infection and to reduce
clinical signs of
respiratory infection and viral excretion caused by adenovirus type 2
infection.
Onset of immunity: one week
Duration of immunity: three years.
Revised: February 2022
AN: 00188/2021 & 00189/2021
Page 2 of 6
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be
reduced
due to maternal antibody interference. However, the vaccine has been
proven to be
of benefit against virulent challenge in the presence of maternal
antibody levels to
CDV, CAV2 and CPV that are likely to be encountered under field
conditions.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Only healthy dogs should be vaccinated. Dogs should not be exposed to
unnecessary risk of infection within the first week after completion
of the
vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low
levels for up
to 8 days a